R OSIGLITAZONE : C URRENT S TATUS In 2007, a meta-analysis of controlled clinical trials found increases in the risk of myocardial infarction and a near-significant increased risk of death from cardiovascular causes when rosiglitazone was compared with placebo or with standard diabetes drugs.[ 5 ] In July 2010, the Health Ministry of India ordered Glaxo Smith Kline to suspend human studies being conducted in 19 sites across India.
1
—
—